- Medicine Name- Cibinqo
- API– Abrocitinib
- Strength– Tablets: 50 mg, 100 mg, and 200 mg
- Manufactured by- Pfizer Inc
Adults with refractory, moderate-to-severe atopic dermatitis, for whom the use of biologics or other systemic pharmacological products is not recommended, or for whom the illness is not sufficiently managed with conventional therapies, may be treated with CIBINQO, a Janus kinase (JAK) inhibitor.
Use Restrictions: It is not advised to combine CIBINQO with other immunosuppressants, biologic immunomodulators, or JAK inhibitors.
Recommended Dosage: Dosage:
- The standard dosage for CIBINQO is 100 mg, to be taken orally once daily. In cases where patients do not demonstrate an adequate response to the standard 100 mg dose, a higher dosage of 200 mg orally once daily is recommended.
- For individuals with moderate renal impairment, the suggested initial dosage is 50 mg once daily. However, if the response is insufficient, the dosage may be increased to 100 mg once daily.
- For CYP2C19 poor metabolizers, the recommended starting dosage is 50 mg once daily. Depending on individual response, the dosage may be adjusted to 100 mg once daily.
CIBINQO is administered orally. It is important to adhere to the prescribed dosage and administration schedule as directed by the healthcare provider. Prior to initiating CIBINQO, it is essential to conduct the recommended testing, evaluations, and procedures outlined in the Full Prescribing Information. Additionally, for any necessary modifications to the dosage due to specific adverse reactions, healthcare professionals should refer to the detailed information provided in the Full Prescribing Information.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.